TriangleMetformin (NCT07693452)
Metformin trial for Appendiceal Mucinous Neoplasm (NCT07693452). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with pseudomyxoma peritonei from presumed appendiceal mucinous tumors. Disease must be recurrent/refractory after surgery with heated abdominal chemotherapy, unresectable, or without planned surgery. Current metformin users are excluded.
The idea: metformin alters cellular energy signaling and may inhibit mTOR growth signaling. This pilot tests taking oral metformin, 850 milligrams daily, for up to eighteen months. Researchers measure whether at least eighty-percent adherence is reached by six months.
This phase 2 study plans 15 patients. Oliver Eng leads at UC Irvine, Orange, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.